Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients

• Main Authors: Luis León-Mateos, Alicia Abalo, Helena Casas, Urbano Anido, Óscar Rapado-González, María Vieito, Mercedes Suárez-Cunqueiro, Antonio Gómez-Tato, Miguel Abal, Rafael López-López, Laura Muinelo-Romay
• Format: Article
• Language: English
• Published: MDPI AG 2020-07-01
• Series: Journal of Clinical Medicine
• Subjects: circulating tumor cells (CTCs); castration-resistant prostate cancer (CRPC); expression arrays; tumor markers
• Online Access: https://www.mdpi.com/2077-0383/9/7/2066

Background: Current therapeutic options in the course of metastatic castration-resistant prostate cancers (mCRPC) reinforce the need for reliable tools to characterize the tumor in a dynamic way. Circulating tumor cells (CTCs) have emerged as a viable solution to the problem, whereby patients with a variety of solid tumors, including PC, often do not have recent tumor tissue available for analysis. The biomarker characterization in CTCs could provide insights into the current state of the disease and an overall picture of the intra-tumor heterogeneity. Methods: in the present study, we applied a global gene expression characterization of the CTC population from mCRPC (<i>n</i> = 9), with the goal to better understand the biology of these cells and identify the relevant molecules favoring this tumor progression. Results: This analysis allowed the identification of 50 genes specifically expressed in CTCs from patients. Six of these markers (<i>HOXB13</i>, <i>QKI</i>, <i>MAOA</i>, <i>MOSPD1</i>, <i>SDK1</i>, and <i>FGD4</i>), were validated in a cohort of 28 mCRPC, showing clinical interest for the management of these patients. Of note, the activity of this CTC signature was related to the regulation of MYC, a gene strongly implicated in the biology of mCRPC. Conclusions: Overall, our results represent new evidence on the great value of CTCs as a non-invasive biopsy to characterize PC.